Coherent (NYSE:COHR) draws attention as accelerating AI infrastructure spending lifts demand for optical components across ...

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Q2 2026 earnings call recap: guidance cut, CEO transition, oncology pipeline updates, and key catalysts—read insights and what’s next.

From matching pixel density to choosing the right monitor arms, these are the five decisions that make a multi-monitor setup ...

Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latestAdvanced ...

"Odd" is the word that analysts are using to describe a potential Bristol-Myers Squibb tie-up with AstraZeneca. AstraZeneca and Bristol Myers Squibb are reportedly in talks to merge and create one of ...

Great work, chemists! Two of the largest petrochemical makers in the Middle East—Sabic and Borouge—say they have been able to ...

Guido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader ...

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership as the Company advances the ...

UK drugmaker AstraZeneca is in talks to combine with US rival Bristol Myers Squibb in a deal that would create one of the ...

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes an undisclosed upfront ...

Rugged systems require safer, more durable battery chemistries along with more robust packaging that can handle harsh ...